Navigation Links
Pharmasset Reports Fiscal First Quarter 2011 Financial Results
Date:2/7/2011

rom the PROPEL study at AASLD 2010

-- Initiated the exploratory interferon sparing ELECTRON trial with PSI-7977 in genotype 2 or 3 HCV infected patients

-- Reported positive 12 week safety and efficacy results from the PROTON trial in genotype 2 or 3 patients

-- Reported 7 and 14 day monotherapy results with PSI-938

-- Announced a clinical collaboration with Bristol-Myers Squibb to investigate the combination of PSI-7977 and BMY-790052 in genotype 1, 2 or 3 treatment naïve HCV patients.

-- Completed a common stock offering raising $123.4 million in net proceeds.

"We continue to make good progress with all of our nucleotide analog programs for HCV," stated Schaefer Price, President and Chief Executive Officer. "We have maintained the momentum of 2010 into 2011 by initiating the interferon sparing ELECTRON trial, as well as a 7977 and 938 combination trial. As we look to better define the role of nucleotide analogs in the future treatment of HCV, we and our partners are planning three interferon-free studies in the first half of 2011, including our own proprietary nucleotide analog combination trial with 7977 and 938. While other DAA combination trials have been impacted by the development of resistance, our nucleotide analog trials continue to demonstrate good antiviral activity, safety and a high barrier to resistance."

Calendar Year 2011 Anticipated Milestones:-- Pharmasset expects to report SVR12 data from its ongoing Phase 2b PROTON trial with PSI-7977 in HCV genotype 2/3 patients in the second quarter of 2011

-- Pharmasset expects to report the 12 week interim analysis from its PROTON trial genotype 1 arms in the second quarter of 2011

-- Pharmasset expects to initiate a Phase 2b trial exploring up to 24 week durations of PSI-7977 and pegylated interferon and ribavirin in the second quarter of 2011

-- Pharmasset expects to initiate a Phase 2 combination study with PSI-7977 and PSI-93
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
2. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
3. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
4. Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART
5. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
6. Roche and Pharmasset To Present the R7128 Monotherapy Resistance Profile
7. Pharmasset Reports First Fiscal Quarter 2008 Financial Results
8. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
9. Pharmasset Commences Dosing R7128 Cohorts 3 and 4 for the Treatment of Chronic Hepatitis C
10. Pharmasset Nominates PSI-7851 as a Lead Development Candidate for the Treatment of Chronic Hepatitis C
11. Pharmasset Receives Notice of Allowance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... 2015 Taiwan,s GNT ... in Taipei on  August 25 ... platform, a targeted drug delivery technology that uses nano-scale ... was part of a joint press conference held by ... (GNT), showcasing GNT,s latest edible gold-based food and beverage ...
(Date:9/1/2015)... 1, 2015 Sargas Pharmaceutical Adherence and ... Drug Adherence m Health applications along with 24 ... of non face-to-face monitoring of twenty minutes per ... of our apps, doctors are now well prepared ... our ONCHIT certified Physician, Pharmacy and Patient portals ...
(Date:9/1/2015)... Agena Bioscience TM today announced the establishment ... commercial and financial hub from which many biotech and life ... in mainland China . "The ... sales with almost sixty MassARRAY ® Systems installed to ... allow us to expand our reach and foster a high ...
Breaking Medicine Technology:GNTbm Updates Developments in the Vaucarrin(TM) annogold Drug Delivery Platform 2GNTbm Updates Developments in the Vaucarrin(TM) annogold Drug Delivery Platform 3GNTbm Updates Developments in the Vaucarrin(TM) annogold Drug Delivery Platform 4GNTbm Updates Developments in the Vaucarrin(TM) annogold Drug Delivery Platform 5SPAC International's Drug Adherence and Chronic Care Management App Now available at Apple App and Google Play stores 2Agena Bioscience Opens Office in Shanghai, China 2
... today announced positive results from a Phase 1 trial ... in vitro anti-pseudomonal activity. The results from ... well tolerated, with a clinical and laboratory safety profile ... toxicity was observed, even at the highest dose regimen ...
... 23 Each year in the United States more than ... These new cases account for 10 percent of the new ... several types of leukemia, the survival rate has not changed ... Golubieski, president of Foundation Venture Capital Group, LLC, a New ...
Cached Medicine Technology:Calixa Therapeutics Announces Positive Phase 1 Results for CXA-101, a Novel Intravenous Cephalosporin Antibiotic with Excellent Anti-Pseudomonal Activity 2Foundation Venture Capital Group Invests in UMDNJ Company Working to Improve Leukemia Treatments 2
(Date:9/1/2015)... (PRWEB) , ... September 01, 2015 , ... ... Vendor “Hair Extension Vending Machine,” is still strongly maintaining her firm’s success in ... and beauty tools. In her upcoming city-to-city tour, Ellis will be providing “Look ...
(Date:9/1/2015)... (PRWEB) , ... September 01, ... ... Professional Background Screeners (NAPBS®) has announced that Edge Information Management has ... by the Background Screening Credentialing Council (BSCC). , “Achieving and maintaining ...
(Date:9/1/2015)... ... September 01, 2015 , ... With former IBMers among its founding members, ... its inception more than 35 years ago. A pilot program begun by the company ... and, not just those intent on pursuing careers in these fields. The program is ...
(Date:9/1/2015)... ... 01, 2015 , ... Royal River Natural Foods, a locally-owned independent natural health ... for 19 years and found that, among those who had a stroke, people who ... is part of the September 2015 issue of “Natural Insights for Well Being,” which ...
(Date:9/1/2015)... , ... September 01, 2015 , ... The FSH ... incurable disease, facioscapulohumeral muscular dystrophy (FSHD), will be the beneficiary of a collection of ... mission – to raise awareness of the FSH Society and further FSHD research. ...
Breaking Medicine News(10 mins):Health News:Beauty Entrepreneur creates hair extension smart machine and mobile app inspired by UBER technology 2Health News:Edge Information Management Granted Continued NAPBS Accreditation 2Health News:Edge Information Management Granted Continued NAPBS Accreditation 3Health News:Inmar Announces Program to Fuel Student Passion for STEM – with an Unconventional Twist 2Health News:New Study Finds Multivitamins Extend Life After Stroke, Retailer Reports 2Health News:FSH Society Beneficiary of Variety of Fall Fundraising Events 2Health News:FSH Society Beneficiary of Variety of Fall Fundraising Events 3
... food allergens is an important factor in the pathogenesis ... affects up to 28% of infants in the first ... weeks of age and improve gradually over the following ... of the journal Pediatrics, a randomized, controlled trial of ...
... An all religious party organized in New Delhi by Sri the ... an uniform voice against discrimination based on gender and concern was ... the religious leaders were present in the meeting and they were ... and determination of sex which has lead to an increase in ...
... used in the treatment of male erectile dysfunction is found ... with Raynaud’s phenomenon//. ,Raynaud's phenomenon is a disease ... to presence of spasms in the small blood vessels of ... which results in poor circulation of blood and pain. Raynaud’s ...
... main causes of tooth loss worldwide and is the ... with periodontal disease lost 2.8 teeth versus 1.8 teeth ... been found out from research that certain groups of ... ,The study analyzed the effects of several ...
... jog can help patients suffering from major depression, say ... standard antidepressant medications in reducing symptoms in patients with ... exercise didn't seem to matter - what seemed to ... said James Blumenthal, a professor of medical psychology at ...
... study, Women's Health in the Lund Area, was ... the data collected now reveals a small but ... 113:1627-1631]//. This suggests that low-level cadmium exposure may ... population is likely to encounter low-level chronic exposure ...
Cached Medicine News:Health News:Effect of Maternal Diet on Colic Among Breastfed Infants 2Health News:Nine Major Culprits For Tooth Loss Identified By Researchers 2Health News:Nine Major Culprits For Tooth Loss Identified By Researchers 3Health News:The Exposure Of Cadmium And Its Effects On Kidneys 2
...
No. 1. 30 mm conventional blades. Thin well-rounded tips....
Open blade speculum designed for both temporal and superior approach ocular surgery. Thumb screw adjusting mechanism. Manufactured in titanium....
Adjustable lid speculum angled 45 degrees with 17 mm curved solid blades and aspiration ports to remove excess fluid from around the eye during ocular procedures....
Medicine Products: